Investment analysts at StockNews.com assumed coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) in a report released on Sunday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Price Performance
Shares of GLMD opened at $0.39 on Friday. The stock has a market capitalization of $1.96 million, a P/E ratio of -0.12 and a beta of 0.83. Galmed Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $5.47. The firm has a fifty day simple moving average of $0.37 and a two-hundred day simple moving average of $0.38.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last posted its earnings results on Thursday, April 4th. The biopharmaceutical company reported ($0.98) earnings per share for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Read More
- Five stocks we like better than Galmed Pharmaceuticals
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 5/20 – 5/24
- How to Start Investing in Real Estate
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- Do ETFs Pay Dividends? What You Need to Know
- These 2 Retail Traders Favorites are Nearing Major Breakouts
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
